Pfizer (PFE)

Caribou Biosciences (NASDAQ:CRBU) Chief Executive Officer Rachel Haurwitz said the company is advancing two CRISPR-enabled, off-the-shelf CAR T cell therapy programs, with its lymphoma candidate vispa-cel now “pivotal-ready” and its multiple myeloma program CB-011 continuing in Phase 1 development.

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Pfizer reports Phase 2b obesity drug data showing 15.9% weight loss as FDA expands HYMPAVZI use for hemophilia patients.

The most recent research report on the "Hemostat Powder Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts, an

For a solid yield and strong upside potential, this pharmaceutical stock is worth considering.

They sport recent dividend yields of 3.25%, 6.7%, and a whopping 7.7%.

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.

Arvinas (NASDAQ:ARVN) management outlined a more selective development strategy at a Jefferies-hosted investor discussion, emphasizing internal investment in neurological and oncology programs where the company believes it can create differentiated therapies, while seeking partners for assets that m

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...

Aclaris Therapeutics (NASDAQ:ACRS) executives outlined a busy clinical calendar for the biotechnology company during a fireside chat at the Jefferies 2026 Global Healthcare Conference, highlighting upcoming readouts across its immunology pipeline and a planned Phase 2 asthma study for its lead bispe

Durability, not yield, is the deciding factor.

The most recent research report on the "Avascular Necrosis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts,

These stocks pay between 4.2% and 6.7% in dividends.

Whichever one you choose, you'll need patience before you can see solid returns.

It is finally bouncing back after several challenging years.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

You should consider these strategies if you can't afford to wait out another market crash.

These aren't the most exciting businesses, but they have a lot to offer to long-term investors.

Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

This little-discussed pipeline program could prove to be a big success.

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...